Personalis Intrinsic Value Calculator – Personalis Forecasts Workforce Reduction to Secure Long-Term Financial Stability
December 5, 2023
☀️Trending News
Personalis ($NASDAQ:PSNL), Inc. is a leading biotechnology company focused on unlocking the power of the human genome to create transformative clinical applications. The company recently announced that it is forecasting a workforce reduction to ensure its long-term financial stability. Personalis anticipates that this measure will help extend its cash runway into 2026. The company has outlined several steps it will take in order to achieve its goals. These include reducing staff levels and streamlining business processes, as well as cutting costs in various areas of the company.
In addition, Personalis is looking to optimize its research and development investments and focus on core competencies. Overall, Personalis believes that these measures will bring long-term benefits to the company and its shareholders. By taking this proactive approach, the company aims to secure its financial stability for the years ahead. This, in turn, will help ensure that Personalis can continue to deliver innovative products and services that benefit both patients and healthcare providers.
Share Price
On Monday, PERSONALIS made the difficult announcement that they will be reducing their workforce in order to ensure long-term financial stability. The news caused a spike in the company’s stock which opened at $1.5 and closed at $1.6, representing a 6.8% increase from the previous closing price of $1.5. This indicates that investors are confident in the company’s decision to make these cuts in order to remain financially viable in the long run. While the decision was difficult, the company believes it is the responsible one to make at this time. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Personalis. More…
| Total Revenues | Net Income | Net Margin |
| 70.53 | -112.78 | -149.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Personalis. More…
| Operations | Investing | Financing |
| -59.6 | 46.59 | 1.73 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Personalis. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 226.64 | 75.43 | 3.08 |
Key Ratios Snapshot
Some of the financial key ratios for Personalis are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -2.7% | – | -159.6% |
| FCF Margin | ROE | ROA |
| -108.5% | -43.0% | -31.0% |
Analysis – Personalis Intrinsic Value Calculator
At GoodWhale, we have taken an in-depth look at the fundamentals of PERSONALIS. After careful consideration, our proprietary Valuation Line has calculated the fair value of a PERSONALIS share to be around $4.7. However, the current price of a PERSONALIS stock is only $1.6 – meaning that it is significantly undervalued, by 65.9%. This presents an amazing opportunity for investors to purchase a stock at below market value. More…
Peers
Personalis Inc is a leading provider of precision medicine solutions. The company offers a suite of products and services that enable its customers to develop and commercialize precision medicine therapies. The company’s products and services include genomic sequencing, bioinformatics, and clinical decision support tools. The company has a strong focus on cancer, rare disease, and pharmacogenomics. Personalis Inc has a number of competitors, including Diaceutics PLC, Charles River Laboratories International Inc, and Biodesix Inc.
– Diaceutics PLC ($LSE:DXRX)
Diaceutics PLC is a diagnostic services company. The company operates a laboratory that provides diagnostic testing services for the detection of genetic diseases. The company also manufactures and sells diagnostic kits and products. The company’s products are used by healthcare professionals in the diagnosis and treatment of genetic diseases.
– Charles River Laboratories International Inc ($NYSE:CRL)
Founded in 1947, Charles River Laboratories International, Inc. is a leading provider of drug discovery, development and manufacturing services to the global pharmaceutical and biotechnology industries. The company has helped advance the science of drug development and commercialization for over 70 years, providing services and products to support customers throughout the drug development process.
Charles River Laboratories International, Inc. has a market cap of $10.47B as of 2022 and a Return on Equity of 13.86%. The company’s market cap is a measure of its value on the stock market, and its ROE is a measure of its profitability. The company’s market cap and ROE both indicate that it is a large and profitable company.
– Biodesix Inc ($NASDAQ:BDSX)
Biodesix Inc is a biotechnology company that develops and commercializes blood-based molecular diagnostic tests for the early detection and treatment of cancer. The company’s tests are based on next-generation sequencing and machine learning.
Biodesix’s market cap is 45.58M as of 2022. The company has a Return on Equity of -655.98%. The company’s tests are based on next-generation sequencing and machine learning.
Summary
Personalis Inc. (NASDAQ: PSNL) is a genomic services provider, providing a range of services related to genomics. Despite the challenging economic environment, the company recently reported that its cash runway is expected to extend into 2026, largely due to a workforce reduction plan. This news appears to have had a positive impact on the stock price, with it rising the same day. For investors looking for exposure to the genomics space, Personalis Inc. may be worth considering due to its strong cash position and promising outlook.
